JP MORGAN/CALL/MODERNA/220/0.1/17.01.25 | Real-time Bid/Ask 09:01:38 2024-05-23 EDT | ||
| 1.16 EUR / 1.24 EUR | -1.64% |
|
| Current month | +480.95% | ||
| 1 month | +662.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 1.16 | -4.92% |
| 24-05-22 | 1.22 | +110.34% |
| 24-05-21 | 0.58 | +5.45% |
| 24-05-20 | 0.55 | +44.74% |
| 24-05-17 | 0.38 | -2.56% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 09:01 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JL0VUY |
| ISIN | DE000JL0VUY9 |
| Date issued | 2023-04-12 |
| Strike | 220 $ |
| Maturity | 2025-01-17 (239 Days) |
| Parity | 10 : 1 |
| Emission price | 2.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.03 € |
|---|---|
| Lowest since issue | 0.11 € |
| Spread | 0.08 € |
| Spread % | 6.45% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Warrants
- Warrant
